PT-141 neusspray, or bremelanotide nasal spray, is a research peptide studied for libido. Learn how it works, dosing, duration, and overall safety.
PT-141 neusspray is the Dutch term for PT-141 nasal spray, an intranasal form of bremelanotide that activates melanocortin receptors in the brain. No intranasal bremelanotide product is FDA-approved for human use in the United States. Almost everything sold under this name is research-grade chemical rather than a medicine.
What Is PT-141 Neusspray?
PT-141 is a synthetic cyclic heptapeptide developed by Palatin Technologies. It was first studied as a sunless tanning agent, and trial participants reported increased sexual desire as a side effect. That finding moved the compound into sexual medicine research.
The peptide binds melanocortin receptors, mainly MC4R, in the hypothalamus and limbic system. Those receptors help regulate appetite, energy balance, and sexual motivation.
People searching for a nasal PT-141 product are usually shopping for lyophilized powder plus sterile supplies to prepare their own solution in a laboratory setting.
How PT-141 Works and How Fast It Takes Effect
Bremelanotide works in the central nervous system rather than on blood vessels, so it targets desire rather than blood flow. It stimulates MC4R signaling in the brain.
That central mechanism separates PT-141 from PDE5 inhibitors such as sildenafil, which relax vascular smooth muscle and act on circulation.
Onset is fairly quick. In nasal studies, participants reported effects starting about 30 to 60 minutes after dosing. Most people asking pt-141 how long does it take to work are seeing that same window, while the subcutaneous injection starts working in roughly 45 minutes.
PT-141 Nasal Spray vs Injection
The two routes differ in dose, consistency, and regulatory status. The table below compares pt-141 nasal spray vs injection using published trial data and FDA label information.
| Feature | PT-141 Nasal Spray | PT-141 Injection (Vyleesi) |
|---|---|---|
| FDA approval | None | Approved in 2019 for premenopausal women with HSDD |
| Typical dose in studies | 7.5–20 mg intranasal | 1.75 mg subcutaneous |
| Onset | About 30–60 minutes | About 45 minutes |
| Duration of effect | Roughly 4–6 hours | Roughly 4–6 hours |
| Dose consistency | Lower; depends on spray technique | High |
| Common irritation | Nasal burning or dryness | Injection-site reactions |
| Blood pressure | Elevated in trials | Elevated; boxed warning |
The injected form is more predictable because the full dose reaches circulation, while intranasal absorption varies with technique and nasal health.
Nasal delivery was largely abandoned during clinical development because of cardiovascular signals. That history matters when evaluating any new enthusiasm for an intranasal product.
How Long Does PT-141 Last?
Bremelanotide has a half-life of about 2.7 hours after subcutaneous dosing, and most reported effects fade within four to six hours. The direct answer to how long does pt-141 last is essentially one evening.
Nausea and flushing usually appear within the first hour and settle faster than the desire-related effects. Individual response still varies widely.
Duration does not change much between nasal and injected routes in the published data, though weak nasal absorption can shorten the useful window for some people.
Repeated use is a separate concern. Frequent dosing over weeks has been linked to skin darkening, including on the face and gums, and that hyperpigmentation can be slow to reverse.
How to Make PT-141 Nasal Spray and Typical Research Doses
Reconstituting a peptide into a nasal solution is a laboratory task that requires sterile technique. The general steps are to dilute lyophilized bremelanotide with bacteriostatic water or sterile saline, filter the solution through a 0.22-micron filter, and transfer it into a sterile nasal spray bottle.
Concentration math is where most errors happen. A 10 mg vial diluted into 5 mL gives 2 mg/mL, and a standard pump delivers roughly 0.1 mL per actuation. That is about 0.2 mg per spray, far below the milligram doses used in nasal trials.
Anyone researching how to make pt-141 nasal spray should focus on sterility, pH, and accurate math rather than on a specific recipe. Contaminated or mis-dosed solutions are a genuine risk.
PT-141 Peptide Dosage Chart
| Route | Dose studied | Onset | Duration | Notes |
|---|---|---|---|---|
| Intranasal | 7.5 mg | 30–60 min | 4–6 hours | Lower dose used in early trials |
| Intranasal | 12.5 mg | 30–60 min | 4–6 hours | Common in nasal studies |
| Intranasal | 20 mg | 30–60 min | 4–6 hours | Higher dose; more side effects |
| Subcutaneous | 1.75 mg | ~45 min | 4–6 hours | FDA-approved dose (Vyleesi) |
The pt-141 peptide dosage chart above reflects published research figures and is not a dosing recommendation for any individual.
Doses are not interchangeable between routes because bioavailability differs. A milligram given intranasally does not equal a milligram injected.
Side Effects, Safety, and Legal Status
The most frequently reported side effects in trials are:
- Nausea, the most common complaint, especially at higher doses
- Flushing and headache
- Nasal irritation or injection-site reactions
- Rises in blood pressure
- Skin darkening with repeated use
Bremelanotide raises blood pressure. Vyleesi carries a boxed warning about this effect, and the drug is contraindicated in people with uncontrolled hypertension or known cardiovascular disease.
PT-141 nasal spray is not FDA-approved and is sold only as a research chemical in the United States, which places responsibility for safe handling on the buyer. It is not a legal prescription medication in nasal form.
No one should self-dose a research peptide without medical supervision. A healthcare professional can discuss approved options and screen for cardiovascular risk factors.
Frequently Asked Questions
Is PT-141 nasal spray FDA-approved?
No. No intranasal bremelanotide product has been approved by the FDA for human use. The only approved bremelanotide product in the United States is Vyleesi, a 1.75 mg subcutaneous injection approved in 2019 for premenopausal women with hypoactive sexual desire disorder.
How long does PT-141 nasal spray take to work, and how long do the effects last?
Nasal bremelanotide typically begins working about 30 to 60 minutes after dosing, and reported effects usually fade within four to six hours. The subcutaneous injection has an onset of roughly 45 minutes and a similar duration. Nausea and flushing tend to appear in the first hour and settle sooner than the desire-related effects.
Can you legally buy PT-141 nasal spray in the US?
PT-141 nasal spray is not an approved drug, so it is sold as a research chemical labeled not for human consumption. Purity and concentration vary between vendors, and there is no pharmacy-grade nasal product. Anyone considering bremelanotide should speak with a healthcare professional about approved options instead.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.